vTv Therapeutics (NASDAQ:VTVT - Get Free Report) is anticipated to release its earnings data before the market opens on Thursday, May 8th. Analysts expect vTv Therapeutics to post earnings of ($0.90) per share for the quarter.
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.87) by $0.32. The business had revenue of $0.02 million during the quarter.
vTv Therapeutics Price Performance
Shares of vTv Therapeutics stock traded down $0.05 during trading on Tuesday, hitting $21.68. 2,607 shares of the company's stock traded hands, compared to its average volume of 23,261. The company has a market cap of $69.14 million, a PE ratio of -4.78 and a beta of 0.77. The firm's fifty day moving average price is $18.38 and its 200 day moving average price is $16.57. vTv Therapeutics has a twelve month low of $12.12 and a twelve month high of $29.01.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on VTVT shares. HC Wainwright started coverage on vTv Therapeutics in a research note on Wednesday, April 9th. They issued a "buy" rating and a $36.00 price objective on the stock. StockNews.com initiated coverage on vTv Therapeutics in a research note on Wednesday, April 16th. They issued a "sell" rating on the stock.
Check Out Our Latest Stock Report on vTv Therapeutics
vTv Therapeutics Company Profile
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Featured Articles
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
